Last reviewed · How we verify
TJO-083
TJO-083 is a small molecule that targets the SGLT2 receptor.
TJO-083 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TJO-083 |
|---|---|
| Sponsor | Taejoon Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
TJO-083 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin, which are used to treat type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients (PHASE3)
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TJO-083 CI brief — competitive landscape report
- TJO-083 updates RSS · CI watch RSS
- Taejoon Pharmaceutical Co., Ltd. portfolio CI